Hematologic Malignancy
Myelodysplastic Syndrome with Low Blasts
CI-CAN-00003371MDS-LBExplore in graph →
Hematologic1 active trials
- NCIt
- C200389
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003371MDS-LBExplore in graph →
Clinical trials
23 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 | 26 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 2 | 18 | Fred Hutchinson Cancer Center |
| 1 |
| Dec 12, 2022 |
| clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2023source: clinicaltrials